Scabies Market Poised for Revolutionary Growth by 2032, Predicts DelveInsight

Globe and Mail

31-03-2025

The scabies market is steadily advancing and is driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's ' Scabies - Market Insight, Epidemiology, And Market Forecast - 2032 ″ report offers an in-depth understanding of the Scabies, historical and forecasted epidemiology as well as the Scabies market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Scabies Market Report:
• The total Scabies market size is estimated to grow with a significant CAGR during the study period (2019-2032).
• Scabies, a highly contagious skin disease, impacts approximately 200 to 300 million people worldwide each year, with higher prevalence in tropical regions and developing countries.
• In 2021, scabies accounted for 5.3 million DALYs, with 206.6 million prevalent cases and 622.5 million new cases, predominantly affecting children and young individuals.
• In January 2025, A recent article was published on Cureus that examines the psychological impact of scabies, highlighting that severe itching associated with the condition can lead to insomnia, concentration difficulties, and social disruptions. These challenges may contribute to the development of post-traumatic stress disorder (PTSD) in affected individuals, emphasizing the need for comprehensive care that addresses both the physical and mental health aspects of scabies.
• An August 2024 article discussed a phase 2 trial demonstrating that a 3 mg dose of ivermectin effectively treated scabies in children aged 2–4 years. By day 14, 90 out of 99 cases had resolved, with only mild side effects in seven participants, supporting its use in global scabies control efforts.
• Leading companies in the Scabies market include Merck & Co., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Renaissance Pharma Inc., and others.
Scabies Overview
Scabies is a highly contagious skin condition caused by the Sarcoptes scabiei mite, which burrows into the skin, leading to intense itching and rash. It spreads through direct skin-to-skin contact and is prevalent in crowded living conditions, particularly in resource-limited settings. The condition is a significant public health concern worldwide, affecting millions annually, with a higher burden in tropical and developing regions. Scabies can lead to secondary bacterial infections and complications if left untreated. Treatment typically involves topical or oral medications, such as permethrin and ivermectin, to eliminate the mites and prevent reinfestation. Despite available therapies, challenges like treatment resistance, reinfection, and limited access to healthcare in endemic regions continue to impact disease control.
Scabies Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Download the report to understand which factors are driving Scabies epidemiology trends @ Scabies Epidemiology Forecast
Scabies Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Scabies market or expected to be launched during the study period. The analysis covers the Scabies market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Scabies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Scabies Market Strengths
• The high prevalence of scabies worldwide, particularly in developing regions, drives the demand for effective treatment options.
• Ongoing research and new therapeutic developments, including oral and combination therapies, are improving treatment efficacy and accessibility.
Scabies Market Weaknesses
• In low-income and remote areas, lack of healthcare infrastructure and limited availability of medications hinder effective scabies management.
• Issues such as drug resistance, reinfestation due to poor hygiene conditions, and the need for community-wide treatment strategies make disease eradication difficult.
Scope of the Scabies Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Scabies Companies: Merck & Co., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Renaissance Pharma Inc., and others.
• Scabies Therapeutic Assessment: Scabies currently marketed, and Scabies emerging therapies
• Scabies Market Dynamics: Scabies market drivers and Scabies market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Scabies Unmet Needs, KOL's views, Analyst's views, Scabies Market Access and Reimbursement
To learn more about the key players and advancements in the Scabies Treatment Landscape, visit the Scabies Market Analysis Report
Table of Contents
1. Scabies Market Report Introduction
2. Executive Summary for Scabies
3. SWOT analysis of Scabies
4. Scabies Patient Share (%) Overview at a Glance
5. Scabies Market Overview at a Glance
6. Scabies Disease Background and Overview
7. Scabies Epidemiology and Patient Population
8. Country-Specific Patient Population of Scabies
9. Scabies Current Treatment and Medical Practices
10. Scabies Unmet Needs
11. Scabies Emerging Therapies
12. Scabies Market Outlook
13. Country-Wise Scabies Market Analysis (2019–2032)
14. Scabies Market Access and Reimbursement of Therapies
15. Scabies Market Drivers
16. Scabies Market Barriers
17. Scabies Appendix
18. Scabies Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: [phone]
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/